Sanofi India (NSE:SANOFI) Change In Payables And Accrued Expense : ₹0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2003. Start your Free Trial

What is Sanofi India Change In Payables And Accrued Expense?

Sanofi India's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was ₹0 Mil. It means Sanofi India's Accounts Payable & Accrued Expense stayed the same from Dec. 2024 to Mar. 2025 .

Sanofi India's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was ₹0 Mil. It means Sanofi India's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Dec. 2024 .

Sanofi India Change In Payables And Accrued Expense Historical Data

The historical data trend for Sanofi India's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi India Change In Payables And Accrued Expense Chart

Sanofi India Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Sanofi India Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Sanofi India Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

Sanofi India Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Sanofi India's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi India Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi India Ltd (NSE:SANOFI) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

500674:India

Address

Saki Vihar Road, Sanofi House, CTS Number 117-B, L&T Business Park, Powai, Mumbai, MH, IND, 400072

Website

https://www.sanofiindialtd.com

Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and other export markets.

Sanofi India Headlines

No Headlines